Business
Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) (hereinafter referred to as the "Specifications") have been officially published in the Chinese Journal of Laboratory Medicine. The Specifications aim to offer standardized protocols for micro
About this update from Everest Medicines Ltd.
[{"type":"text","content":"SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025) (hereinafter referred to as the "Specifications") have been officially published in the Chinese Journal of Laboratory Medicine. The Specifications aim to offer standardized protocols for microbiology laboratory professionals and clinicians to conduct and interpret in vitro antimicrobial susceptibility testing (AST) of eravacycline. It supports rational clinical use of eravacycline based on standardized evidence and enhances the accuracy and consistency of susceptibility testing results across clinical microbiology laboratories, thereby better addressing the challenges of treating multidrug-resistant (MDR) and complicated infections.","length":1018,"tagName":"p"},{"type":"text","content":"The Specifications were jointly developed by the Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (hereinafter referred to as the "ChinaCAST"), the Clinical Microbiology Laboratory Specialized Committee of Chinese Hospital Association, and the Chinese Committee on Antimicrobial Susceptibility Testing, affiliated to the European Committee on Antimicrobial Susceptibility Testing (EUCAST).","length":463,"tagName":"p"},{"type":"text","content":"As a novel fluorocycline antimicrobial, eravacycline possesses broad-spectrum antibacterial coverage, potent activity, and favorable safety and efficacy in comparison to a carbapenem in the registrational trials. It is widely applied in the treatment of multidrug-resistant (MDR) pathogens and complicated intra-abdominal infections. The Specifications comprehensively outline three key areas: the antimicrobial mechanism and features of eravacycline, the AST methods, and clinical breakpoints for result interpretation. It emphasizes the standardization of procedures and accuracy of interpretation, and covers leading AST methodologies including broth microdilution, gradient diffusion (MTS/Etest), and disk diffusion methods, along with defined quality control parameters a...